Cunha S, Amaral M H, Lobo J M Sousa, Silva A C
Laboratory of Pharmaceutical Technology/Centre of Research in Pharmaceutical Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, P-4050-313 Porto Portugal..
Curr Med Chem. 2016;23(31):3618-3631. doi: 10.2174/0929867323666160824162401.
Alzheimer's and Parkinson's diseases are prevalent neurodegenerative disorders worldwide, which are essentially related to aging. Within the remarkable era of nanomedicine, nowadays several delivery systems have been suggested to improve the treatment of these disorders, namely, liposomes, micelles, nanoparticles (polymeric, lipid, metallic and inorganic), exosomes, dendrimers and fullerenes. The advantage that has been claimed to these delivery systems is that they facilitate the passage of drugs through the blood brain barrier (BBB), enabling targeting before body degradation, and increasing therapeutic efficacy, comparied to conventional pharmaceutical dosage forms. This review article provides a state of the art regarding the drug delivery systems that have been studied for the treatment of Alzheimer's and Parkinson's diseases. It begins with a brief description of the central nervous system (CNS) and the mechanisms involved in the development of these diseases. Later, some examples of drugs used in the treatment of these neurodegenerative diseases are presented, which are currently available in conventional pharmaceutical dosage forms, and in new drug delivery systems that are under development.
阿尔茨海默病和帕金森病是全球普遍存在的神经退行性疾病,它们本质上与衰老相关。在纳米医学的非凡时代,如今已提出多种给药系统来改善这些疾病的治疗,即脂质体、胶束、纳米颗粒(聚合物、脂质、金属和无机)、外泌体、树枝状大分子和富勒烯。据称这些给药系统的优势在于,与传统药物剂型相比,它们有助于药物通过血脑屏障(BBB),在药物被身体降解之前实现靶向给药,并提高治疗效果。这篇综述文章提供了关于已研究用于治疗阿尔茨海默病和帕金森病的药物递送系统的最新情况。文章首先简要描述了中枢神经系统(CNS)以及这些疾病发生发展所涉及的机制。随后,介绍了一些用于治疗这些神经退行性疾病的药物实例,这些药物目前有传统药物剂型,以及正在研发的新型药物递送系统。